Doudna’s creature (Mammoth Biosciences) and Zhang’s company (Sherlock Biosciences) are developing CRISPR-based coronavirus tests similar to a home pregnancy test: portable, cheap, fast, and simple. Both will be easily adapted to detect any new emerging virus. Both received emergency use authorizations in the US in the fall of 2020 and hope to enter the market by the end of 2021. According to this piece by Walter Isaacson, competition is hot but all the intellectual property questions have been put aside for common good.
It is Science but it could be mistaken for The CRISPR Journal. The latest issue indeed runs three papers by three CRISPR aces – David Liu, Jennifer Doudna, and Feng Zhang – about the cutting-edge fields of 
CRISPeR FRENZY 